Bioactive glass,a new tool for the treatment in the diabetic foot recalcitrant osteomyelitis: A case series with 24-month follow-up |
| |
| Affiliation: | 1. Department of Orthopedics, Naval Hospital Bremerton, 1 Boone Road, Bremerton, WA, 98312 USA;2. Family Foot and Leg Center Surgical Fellowship Program, Naples, FL, USA;3. Jerry L Pettis Memorial Veterans Hospital, Loma Linda, CA, USA;1. OrthoKids Clinic, Ahmedabad, Gujarat, India;2. OrthoKids Clinic, 7th Floor, Golden Icon, Opp. Medilink Hospital, Near Shivranjini Flyover, Satellite, Ahmedabad 380015, India;1. Faculty of Medicine, Mansoura University, Algomhoria Street, 35516, Egypt;2. Faculty of Medicine, Port-Said University, 41523, Egypt;1. Department of Orthopaedic, Trauma and Reconstructive Surgery, Antoine Béclère Hospital, AP-HP, Paris Sud University, 157 rue de la Porte de Trivaux, 92140 Clamart, France;2. Laboratory of Bioengineering and Biomechanics for Bone Articulation (B2OA – UMR CNRS 7052), Paris-Diderot University, 10 avenue de Verdun, 75010 Paris, France |
| |
| Abstract: | BackgroundThe bioactive glass (BAG) is a promising solution for the reconstruction of bone defects and the eradication of infection in patients with osteomyelitis, however references to the treatment of diabetic foot osteomyelitis are scarce in the literature.MethodsOur experience in patients with diabetic foot osteomyelitis, who required surgical debridement and void filling, in which we use bioactive glass (n = 6), was evaluated. During a minimum follow-up of 24 months, the presence of persistent infection and healing rate, post-surgical complications, surgical reinterventions, degree of osseointegration and BAG-related side effects was analyzed.ResultsAt the end of the follow-up, none of the patients showed signs of persistent infection and the healing rate was 66.6% (4/6).Postoperative complications were noted in 3 patients and two of the them required new surgical intervention, both due to skin coverage or vascular complications.A complete osseointegration in the 66.6% of the patients and no cases of local adverse effects were recorded.ConclusionsThe bioactive glass can be a useful tool in the treatment of certain cases of diabetic foot osteomyelitis, provided that a multidisciplinary approach and strict patient selection is in place.Level of evidenceIV. |
| |
| Keywords: | Osteomyelitis Diabetic foot Bioactive glass BAG-S53P4 Bonalive |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
